Dutch Skyline Diagnostics launches AML prognosis chip in Europe
Rotterdam – Dutch microarray diagnostics specialist Skyline Diagnostics BV has launched a unique microarray for subtyping patients with the most deadly blood cancer AML into different risk groups. AMLprofiler™ replaces current step-by-step diagnosis of cytogenetic, gene and gene expression aberrations with a single test. The test requires isolation of blasts from the bone marrow for cRNA analysis of an Affymetrix platform. Currently, the test is undergoing clinical testing for US market approval. According to Skyline Diagnostics, its test opens up early treatment decision support for physicans and a more personalised and targeted treatment of AML patients with bad prognosis. The chip has been developed with support of the Dutch Center For Translational Molecular Medicine (CTMM) via its ‘BioChip program’. There is already a chip for breast cancer diagnosis on the market.